New P2Y12 inhibitors

Heart

Volumn 97, Issue 15, 2011, Pages 1262-1267

  Storey, Robert F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450 2C19; DILTIAZEM; ELINOGREL; ENOXAPARIN; FONDAPARINUX; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR; UNCLASSIFIED DRUG; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y2 RECEPTOR;

ACUTE CORONARY SYNDROME; ARTERY THROMBOSIS; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; COLON CANCER; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; GENOTYPE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MORTALITY; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; SINUS ARRHYTHMIA; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; VENOUS THROMBOEMBOLISM; BLOOD; DRUG EFFECT; THROMBOCYTE ACTIVATION; THROMBOSIS;

HUMANS; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y1; RECEPTORS, PURINERGIC P2Y2; THROMBOSIS; TREATMENT OUTCOME;

EID: 79960156497     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.184242     Document Type: Review

References (20)

1. 12 receptor. Curr Pharm Des 2006;12:1255-9.
2. Jakubowski J, Winters K, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007;25:357-74.
3. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85. Comprehensive comparison of the onset of action of clopidogrel and ticagrelor loading doses and offset following last maintenance dose.
4. Storey RF, Angiolillo D, Patil S, et al. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO PLATELET substudy. J Am Coll Cardiol 2010;56:1456-62. Largest comparison of the inhibitory effects of ticagrelor and clopidogrel in patients with ACS.
5. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. TRITON-TIMI 38 study showing greater efficacy of prasugrel compared to clopidogrel.
6. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376:1233-43.
7. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923-32. (Pubitemid 350291199)
8. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57. PLATO study showing greater efficacy of ticagrelor compared to clopidogrel including progressive reduction in cardiovascular mortality.
9. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-93. Clinical outcomes including stent thrombosis in patients planned for invasive management.
10. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006-16.
11. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary PCI; a PLATelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131-41.
12. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-8. Ticagrelor more efficacious than clopidogrel regardless of CYP2C19 genotype.
13. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51. (Pubitemid 350007959)
14. Held C, Åsenblad N, Bassand J-P, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO trial. J Am Coll Cardiol 2011;57:672-84.
15. Storey RF, Bliden K, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56:185-93. Prospective study showing no adverse effect of ticagrelor on cardiac or pulmonary function despite an associated adverse effect of dyspnoea.
16. Storey RF, Becker R, Harrington R, et al. Increased incidence of dyspnoea associated with ticagrelor did not appear to adversely affect cardiovascular outcomes in the PLATO study. Stockholm, Sweden: European Society of Cardiology Annual Congress, 2010.
17. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function. Results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2010;122:1056-67.
18. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001;85:401-7. (Pubitemid 32233008)
19. Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008;121:527-34. (Pubitemid 351174272)
20. 12 receptor in restenosis.